Abstract
Based on a single hospital experience of heart valve implantation from 1965 to 2009, the superiority of prosthetic heart valves including Starr–Edwards caged ball valves, Omniscience aortic tilting disc valves, and St. Jude Medical bileaflet valves are reviewed. This review discusses the prominent antithrombogenicity of the Starr–Edwards model 1200 aortic prosthesis under selected conditions, the relatively rarely thrombosed (despite its decreased opening angle) Omniscience aortic valve, the long-term outcomes 10 as well as 30 years after St. Jude Medical valve replacement, and finally the latest results on the significance of patient–aortic prosthesis mismatch in relation to myocardial hypertrophy. The findings described here should be considered in further investigations of cardiac valve prostheses.
Similar content being viewed by others
References
Macmanus Q, Grunkemeier GL, Lambert LE, Teply JF, Harlan BJ, Starr A. Year of operation as a risk factor in the late results of valve replacement. J Thorac Cardiovasc Surg. 1980;80:824–41.
Hayashi J, Nakazawa S, Eguchi S, Ohtani S, Asano K. Long-term outcome of patients who received Starr–Edwards valves between 1965 and 1977. Cardiovasc Surg. 1996;4:281–7.
Isom OW, Spencer FC, Glassman E, Teiko P, Boyd AD, Cunningham JN, Reed GE. Long-term results in 1375 patients undergoing valve replacement with the Starr–Edwards cloth-covered steel ball prosthesis. Ann Surg. 1977;186:310–23.
Barnhorst DA, Oxman HA, Connolly DC, Pluth JR, Danielson GK, Wallace RB, McGoon DC. Long-term follow-up of isolated replacement of the aortic or mitral valve with the Starr–Edwards prosthesis. Am J Cardiol. 1975;35:228–33.
Miller DC, Oyer PE, Mitchell RS, Stinson EB, Jamieson SW, Baldwin JC, Shumway NE. Performance characteristics of the Starr–Edwards model 1260 aortic valve prosthesis beyond ten years. J Thorac Cardiovasc Surg. 1984;88:193–207.
Wain WH, Drury PJ, Ross DN. Aortic valve replacement with Starr–Edwards valves over 14 years. Ann Thorac Surg. 1981;33:562–9.
Roberts DL, DeWeese JA, Mahoney EB, Yu PN. Long-term survival following aortic valve replacement. Am Heart J. 1976;91:311–7.
Brott WH, Zajtchuk R, Bowen TE, Davia J, Green DC. Dipyridamole-aspirin as thromboembolic prophylaxis in patients with aortic valve prosthesis. J Thorac Cardiovasc Surg. 1981;81:632–5.
Stein DW, Rahimtoola SH, Kloster FE, Selden R, Starr A. Thrombotic phenomena with nonanticoagulated, composite-strut aortic prostheses. J Thorac Cardiovasc Surg. 1976;71:680–4.
Warnes CA, McIntosh CL, Roberts WC. Wear of the metallic studs on the composite seat of the 2320 Starr–Edwards aortic valve and its clinical consequences. Am J Cardiol. 1983;52:1062–5.
DeWall R, Pelletier LC, Panebianco A, Hicks G, Schuster B, Bonan R, Martineau J, Yip L. Five-year clinical experience with the Omniscience cardiac valve. Ann Thorac Surg. 1984;38:275–80.
Rabago G, Martinell J, Fraile J, Andrade IG, Montenegro R. Results and complications with the Omniscience prosthesis. J Thorac Cardiovasc Surg. 1984;87:136–40.
Fananapazir L, Clarke DB, Dark JF, Lawson RAM, Moussalli H. Results of valve replacement with the Omniscience prosthesis. J Thorac Cardiovasc Surg. 1983;86:621–5.
Carrier M, Martineau J-P, Bonan R, Pelletier LC. Clinical and hemodynamic assessment of the Omniscience prosthetic heart valve. J Thorac Cardiovasc Surg. 1987;93:300–7.
Bruckhardt D, Hoffmann A, Vogt S, Pfisterer M, Hasse J, Gradel E. Clinical evaluation of the St. Jude Medical heart valve prosthesis. J Thorac Cardiovasc Surg. 1984;88:432–8.
Arom KV, Nicoloff DM, Kersten TE, Northrup WF, Lindsay WG, Emery RW. Ten-year follow-up study of patients who had double valve replacement with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg. 1989;98:1008–16.
Chandran KB. Pulsatile flow past St. Jude Medical bileaflet valve—an in vitro study. J Thorac Cardiovasc Surg. 1985;89:743–9.
Nicoloff DM, Emery RW, Arom KV, Northrup WF III, Jorgensen CR, Wang Y, Lindsay WG. Clinical and hemodynamic results with the St. Jude Medical cardiac valve prosthesis. J Thorac Cardiovasc Surg. 1981;82:674–83.
Chaux A, Czer LSC, Matloff JM, DeRobertis MA, Stewart ME, Bateman TM, Kass RM, Lee ME, Gray RJ. The St. Jude Medical bileaflet valve prosthesis. A 5 year experience. J Thorac Cardiovasc Surg. 1984;88:706–17.
Baudet EM, Oca CC, Roques XF, Laborde MN, Hafez AS, Collot MA, Ghidoni IM. A 5 1/2 year experience with the St. Jude Medical cardiac valve prosthesis. J Thorac Cardiovasc Surg. 1985;90:137–44.
Salem DN, Levine HJ, Pauker SG, Eckman MH, Daudelin DH. Antithrombotic therapy in valvular heart diseases. Chest. 1998;114(5 Suppl):590s–601s.
UK-TIA Study Group. United Kingdom Transient Ischemic Attack Aspirin Trial: interim results. Br Med J. 1988;296:316–20.
Goldman S, Copeland J, Moritz T. Internal mammary artery and saphenous vein graft patency; effect of aspirin. Circulation. 1990;82(Suppl IV):237–42.
Balsano F, Rizzon P, Violi F. Antiplatelet treatment with ticlopidine in unstable angina; a controlled multicenter clinical trial. Circulation. 1990;82:17–26.
Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, Wallace RB, Danielson GK, Orszulak TA, Piehler JM, Schaff HV. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol. 1983;51:1537–41.
Turpie AGG, Gent M, Laupacis A, Latour Y, Gunstensen J, Basile F, Klimek M, Hirsh J. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement. N Eng J Med. 1993;329:524–9.
Hayashi J, Nakazawa S, Oguma F, Niyamura H, Eguchi S. Combined warfarin and antiplatelet therapy after St. Jude Medical valve replacement for mitral valve disease. J Am Coll Cardiol. 1994;23:672–7.
Rahimtoola SH. The problem of valve prosthesis–patient mismatch. Circulation. 1978;58:20–4.
Hayashi J, Nakazawa S, Okazaki H, Ohzeki H, Saito A, Moro H, Yamamoto K, Eguchi S. Long term clinical results with 19 mm or 21 mm standard aortic St. Jude Medical prosthesis. J Heart Valve Dis. 1994;3:537–42.
Adams DH, Chen RH, Kadner A, Aranki SF, Allred EN, Chon LH. Impact of small prosthetic valve size on operative mortality in elderly patients after aortic valve replacement for aortic stenosis: does gender matter? J Thorac Cardiovasc Surg. 1999;118:815–22.
Mehta BH, Bruckman D, Das S, Tsai T, Russman P, Karavite B, Monaghan H, Sonnad S, Shea MJ, Eagle KA, Deeb GM. Implications of increased left ventricular mass index on in-hospital outcomes in patients undergoing aortic valve surgery. J Thorac Cardiovasc Surg. 2001;122:919–28.
Blais C, Dumesnil JG, Baillot R, Simard S, Doyle D, Pibarot P. Impact of valve prosthesis–patient mismatch on short-term mortality after aortic valve replacement. Circulation. 2003;108:983–8.
Medalion B, Lytle BW, McCarthy PM, Stewart RW, Arheart KL, Arnold JH, Loop FD, Cosgrove DM III. Aortic valve replacement for octogenarians: are small valves bad? Ann Thorac Surg. 1998;66:699–706.
Medalion B, Blackstone EH, Lytle BW, White J, Amold JH, Cosgrove DM. Aortic valve replacement: is valve size important? J Thorac Cardiovasc Surg. 2000;119:963–74.
Milano AD, Carlo MD, Mecozzi G, D’Alfonso A, Scioti G, Nardi C, Bortolotti U. Clinical outcome in patients with 19-mm and 21-mm St. Jude aortic prostheses: comparison at long-term follow-up. Ann Thorac Surg. 2002;73:37–43.
Ruel M, Rubens FD, Masters RG, Pipe AL, Bedard P, Hendry PJ, Lam BK, Burwash IG, Goldstein WG, Brais MP, Kaon WJ, Mesana TG. Late incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves. J Thorac Cardiovasc Surg. 2004;127:149–59.
DeCarlo M, Milano AD, Nardi C, Mecozzi G, Bartolotti U. Serial Doppler echocardiographic evaluation of small sized Sorin Bicarbon prostheses. J Thorac Cardiovasc Surg. 2003;126:337–43.
Hanayama N, Christakis GT, Mallidi HR, Joyner CD, Fremes SE, Morgan CD, Mitoff PRR, Goldman BS. Patient prosthesis mismatch is rare after aortic valve replacement: valve size may be irrelevant. Ann Thorac Surg. 2002;73:1822–9.
Tasca G, Brunelli F, Cirillo M, Amaducci A, Mhagna Z, Troise G, Quaini E. Mass regression in aortic stenosis after valve replacement with small size pericardial bioprosthesis. Ann Thorac Surg. 2003;76:1107–13.
Ruel M, AlFald H, Kulik A, Chan KL, Mesama TG, Burmash IG. Prosthesis–patient mismatch after aortic valve replacement predominantly affects patients with preexisting left ventricular dysfunction: effect on survival, freedom from heart failure, and left ventricular mass regression. J Thorac Cardiovasc Surg. 2006;131:1036–44.
Takai H, Eishi K. Consideration of prosthetic-patients mismatch and left ventricular mass regression after implantation of the Carpentier–Edwards pericardial valve in elderly Japanese patients: body surface area may be irrelevant. J Art Org. 2004;7:203–6.
Mannacio VA, De Amicis V, Di Tommaso L, Iorio F, Vosa C. Influence of prosthesis–patient mismatch on exercise-induced arrhythmia: a further aspect after aortic valve replacement. J Thorac Cardiovasc Surg. 2009;138:632–8.
Ali A, Patel A, Ali Z, Abu-Omar Y, Saeed A, Athanasious T, Pepper J. Enhanced left ventricular mass regression after aortic valve replacement in patients with aortic stenosis is associated with improved long-term survival. J Thorac Cardiovasc Surg. 2011;142:285–91.
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented as the Presidential Lecture at the 47th Annual Meeting of the Japanese Society for Artificial Organs, November 13, 2009.
Rights and permissions
About this article
Cite this article
Hayashi, Ji. A 44-year experience of prosthetic heart valve implantation at Niigata University Hospital. J Artif Organs 15, 109–116 (2012). https://doi.org/10.1007/s10047-012-0637-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10047-012-0637-5